Embed Size (px)
Citation preview
Israeli Life Science
Industry Catalog Bio International Convention 2013
Booth 0821
A P R I L 2 2 - 2 5 2 0 1 2 , C H I C A G O , U S A
Israeli Life Science Industry: A Source of Innovation
1 | P a g e
Israel: A Powerhouse of Opportunities Over the last decade, Israel has introduced a wealth of
groundbreaking and valuable innovations in life sciences. Israel’s life
sciences sector is supported by a strong foundation of academic
excellence, including some of the world’s leading research institutes,
renowned R&D facilities and cutting-edge medical centers. Bolstered
by a highly skilled workforce, a flourishing high-tech environment, and
an entrepreneurial spirit, Israeli companies have been joined by
leading multinationals in making Israel a recognized force in the
industry worldwide. Global giants, including Johnson & Johnson,
Perrigo, GE Healthcare, Phillips Medical, Abbott Laboratories, Merck
Serono and Sanofi together with local companies such as Teva, itself a
multinational company, Given Imaging, InSightec, Medinol and others
have been continuously developing and marketing life-changing
medical breakthroughs and innovations.
There are more than 920 active life sciences companies in Israel, with
almost 70% of the companies established in the last decade. The
majority (60%) of Israeli Life Sciences companies are from the medical
device sector. In a relatively short period of time, an impressive 34% of
Israeli Life Science companies have already begun to generate revenue,
demonstrating that Israel has crossed the threshold from an attractive
start-up arena to a source of advanced, commercially viable and
promising businesses. The bridge connecting excellent science to
revenue-generating companies has been established. As proof of the
industry’s development, in 2011 life sciences exports reached $8.9
billion, an increase of 10% over 2010. A rich pipeline of seed companies
promises to perpetuate current growth.
Source: Invest in Israel & IATI
Why Israel? Over 900 life sciences
companies
40% of LS Start-Ups already generate revenue
Source of numerous
blockbuster drugs such as Copaxone and Rebif, generating over $5B in annual sales
First in the world in quality of scientific research institutions (World Economic Forum [WEF] 2011-12)
First in the world for medical device patents per capita, 4th for bio-pharma (US Patent Office 2009)
Pioneers in stem cell research and therapeutics
Extensive international R&D and commercial partnerships
World-renowned academic research institutes such as the Technion and the Weizmann Institute
Unique financing tools and incubator frameworks for start-ups
Medical Devices, 60%
Biotechnology, 17%
Pharmaceutical, 11%
AGBiotech, 2% Health IT, 7% Services, 1% Other, 1%
2 | P a g e
Israel’s Competitive Edge Academia and Research Approximately 50% of all academic research funding in Israel is in
the field of life sciences, and institutions such as the Hebrew
University of Jerusalem, Tel Aviv University, Ben Gurion University of
the Negev, the Technion-Israel Institute of Technology and the
Weizmann Institute of Science have played dominant roles in
advancing biotech R&D. In fact, over the past five years, the
Weizmann Institute was ranked twice as the top international
academic institution in the world for scientists to conduct research
in life sciences. In 2008, it was followed by the Hebrew University of
Jerusalem and in 2010, it was ranked second. This stems from
impressive levels of R&D funding and highly skilled and creative
manpower, which continues to generate new patents in the field.
Cluster Effect Many of Israel’s achievements in the life sciences sector stem from
the fact that over 90% of the population resides within two hours
driving time of each other and within close proximity to seven major
universities and industrial clusters. This cluster effect creates
economies of scale, and allows for better information sharing and
synergies between the companies.
Highly Educated and Highly Skilled
50% of the population aged 25-34 has attained at least tertiary
education, placing it sixth in the world behind Singapore, Japan, and
Korea (IMD Competitiveness Yearbook 2009). Approximately 24% of
Israel’s workforce holds university degrees - placing it third in the
industrialized world after the US and The Netherlands. Israel is
ranked second in the world in the percentage of engineers and
scientists in the work force (IMD 2009).
Entrepreneurial Spirit and Ingenuity
The exceptional volume of life science start-ups and patents attests to the entrepreneurial and
risk-taking climate in Israel. Israeli researchers and entrepreneurs overcome technological barriers
and solve development problems within a short period of time and at a fraction of the cost of
some of their larger and more affluent competitors overseas.
Source: Invest in Israel
3 | P a g e
Rapid Research to Financial Return The last few years have witnessed several significant Israeli life sciences “exit” transactions with
investors realizing impressive returns via IPOs, mergers and acquisitions. Close to 60 life science
companies went public on the Tel Aviv Stock Exchange (TASE) in recent years, among them
BiolineRx, Biondvax, Brainsway, Intec, Mazor, Prolor, Pluristem, Hadasit
Bio Holdings and Nasvax, and approximately 15 Israeli companies have gone public on foreign
exchanges, mainly in the US. According to the IVC Research Center, the value of M&As and IPOs in
Israeli life sciences companies totaled $822 million in 2009.
Source: Invest in Israel
Revenue 39%
Pre-Clinical 13%
Clinical 25%
Seed - 14%
Other - 9%
Companies Development Stage
Source: IATI Database 2012
4 | P a g e
Meet the 2013 Bio Israeli Delegation
On behalf of the organizers and partners, we would like to
introduce you to the 2013 Bio Israeli Delegation. Nineteen
remarkable companies are attending, spanning the spectrum of
Israel’s vigorous life science community, from innovative start-
ups to established companies. Please take the time to explore
their innovative solutions which you can find in this catalog.
We hope you will take the time to schedule a meeting with
some of these companies and see for yourself why Israel is
driving innovation in the life sciences industry. You can visit the
Israel national pavilion at Booth 0821.
Additionally, most of the Israeli companies are participating in
the Bio Business Forum one-on-one partnering service, and
you can find them in the online system at:
http://convention.bio.org/partner/
Meet the Sponsoring Organizations
The sponsoring organizations of the Israeli delegation provide a
full array of support and services to nurture the development of
industry and innovation:
The Office of the Chief Scientist (OCS) is
responsible for the encouragement of
industrial R&D. The OCS annually grants
financial support to hundreds of projects
spanning from incipient concepts within a
pre-seed framework, through seed stage companies in
incubators, to start- up companies and R&D projects of revenue
generating enterprises. In the international arena, the OCS is
vigorously pursuing several avenues of industrial R&D
collaboration between Israeli companies and foreign companies,
both through governmental and global corporate agreements.
The OCS grants preferential support to life sciences companies
and recently launched a government backed life sciences VC
Fund – a joint venture between the government and
international private sector.
Schedule of Events Monday April 22, 2013| 08:00-12:00 Reception hosted by the Israeli Economic
Mission to the Midwest at the offices of
Katten, Muchin, Rosenman LLP (525 W.
Monroe, Chicago IL)
For information and RSVP please visit
www.itrade.gov.il/us-chicago/bio
April 22-25, 2013
Companies exhibiting and holding
meetings at the Israel national pavilion -
Booth #0821
Monday April 22, 2013 | 12:00-17:00
Exhibition and Partnering
Tuesday April 23, 2013
Exhibition and Partnering | 10:00-17:00
Panel Discussion: Can Israel Become the
next Biotech Start-up Nation? |9:00-9:45
Wednesday April 24, 2013 | 10:00-17:00
Exhibition and Partnering
Thursday April 25, 2013 | 10:00-12:00
Exhibition and Partnering
5 | P a g e
MATIMOP is Israel’s national agency for international cooperation in
industrial R&D. MATIMOP implements the international R&D policy of the
Office of the Chief Scientist (OCS), facilitating joint ventures and providing
access to funding. MATIMOP is sponsoring the construction of the Israeli
Pavilion at the BIO Convention.
The Israel Advanced Technology Industries (IATI) is Israel’s largest umbrella
organization for companies, organizations, and individuals in the high tech and
life science sectors. In a country like Israel where innovation is a national
mindset, IATI’s mission is to strengthen the Israeli high tech and life science
industries across the whole value chain and create global, technological and
innovational leadership.
The US-Israel Science and Technology Foundation supports programs to
create a seamless infrastructure for industry, academia and government for
the mutual benefit for the economies of the US and Israel.
The Foreign Trade Administration at the Ministry of Industry, Trade and
Labor, is responsible for managing and directing the international trade policy
of the State of Israel. The main fields of activity include activities for the
promotion of trade and export, initiating and maintaining trade agreements
for the improvement of Israel’s trade conditions, attracting and encouraging
foreign investments and creating strategic cooperation with foreign
companies.
The Enterprise Europe Network (EEN) is made up of over 600 partner
organizations in more than 50 countries, promoting competitive and
innovative international cooperation. EEN Israel consists of three Israeli
partners: ISERD-MATIMOP – EEN Israel's coordinator which is also in charge of
R&D issues (Uri Fishelson - [email protected]); Manufacturers Association of
Israel (MAI) in charge of technology transfer (Sima Amir -
[email protected]) and The Israel Export and International
Cooperation Institute (IEICI) in charge of commercial cooperation (Gil
Oren - [email protected]).
6 | P a g e
Israeli Company Profiles Company Name Page
BioCEP Ltd.
9
BioLineRx 10
Brainsway 11
Compugen
12
ElMindA Ltd. 13
Foamix 14
HIL Applied Medical
15
7 | P a g e
Immune Pharmaceuticals
Ltd. 16
Immune System
Key Ltd.
17
IonMed Ltd 18
ITTN 19
Oramed
Pharmaceuticals
Inc
20
PixCell Medical Technologies Ltd.
21
Pluristem Therapeutics Inc
22
PolyPid Ltd. 23
8 | P a g e
Protalix Biotherapeutics
24
Proteologics 25
RDD Pharma Ltd 26
Shulov Innovative Science Ltd
27
9 | P a g e
Company Profile:
BioCEP Ltd., an Israeli biotech company, develops
and manufacturers novel cell isolation
technologies. BioCEP’s first product, the CEPir, is a
rare cell isolation platform which effectively
isolates cells in a gentle, flow through manner.
CEPir isolated cells are held in stasis within the
system and can therefore be used in downstream
applications.
BioCEP markets the CEPir to research and
development labs and companies directly and via
distributors. BioCEP also partners with research
entities for the joint development of novel clinical
and diagnostic applications which can be realized
over the CEPir platform due to its supremacy.
BioCEP seeks to collaborate with partners for joint
research efforts and to expand its reach via
additional distributors.
Technology Description:
The CEPir, Cell Enrichment Process for Isolation of Rare Cells, offers a
novel, flow through approach to immunomagnetic isolation. Tagged
cells flow through the system and are held in stasis in one of 4
isolation areas. The unique design enables supreme recovery levels at
high purity levels. As the cells are held in stasis, they maintain their
original properties, enabling downstream analysis and applications.
The CEPir effectively isolates cells from various clinical sources such
as, bone marrow, peripheral blood, neonatal cord blood, pleural, peritoneal and cerebrospinal
fluids. CEP's results far surpass those of state-of-the-art systems, enabling rare cell isolation with
99% viability and high purity and yield rates.
With its gentle yet effective approach and its ability to isolate rare cells of even 1 in 109th, the CEPir
is poised to enable novel developments in cutting edge fields such as immunotherapy,
regenerative medicine, isolation of rare circulating tumor cells (CTCs) and isolation of whole, rare
fetal cells for noninvasive prenatal diagnosis. The CEPir is a research-use only device.
Company Name: BioCEP Ltd.
Contact Details
Address: POB 1008
Phone: ++972- 4-682-8827
Fax: ++972- 4-692-3753
Email: [email protected]
Website: www.biocep.com
Exhibition Representatives
Name: Hannoch Markshied, CEO
E-mail: [email protected]
Contact Person
Name: Rachel Leibovitze
E-mail: [email protected]
Category: Cell Research Tools
10 | P a g e
Company Profile:
BioLineRx (NASDAQ: BLRX) is a
biopharmaceutical development company
dedicated to building a portfolio of products for
unmet medical needs or with advantages over
currently available therapies. BioLineRx’s current
portfolio consists of six clinical stage candidates
and eight products in various pre-clinical
development stages for a variety of indications,
including cancer, central nervous system
diseases, infectious diseases, cardiovascular and
autoimmune diseases.
BioLineRx acquires molecules mainly from
biotechnological incubators and academic
institutions, develops them through pre-clinical
and clinical stages and then partners with
pharmaceutical companies for advanced clinical
development and commercialization.
Therapeutic Product Pipeline:
Company Name: BioLineRx Ltd.
Contact Details
Address: 19 Hartum St.
Phone: +972-2-548-9100
Fax: +972-2-548-9101
Email: [email protected]
Website:www.biolinerx.com
Exhibition Representatives
Name: David Malek
E-mail: [email protected]
Contact Person
Name: David Malek
E-mail: [email protected]
Category: Drug Development
11 | P a g e
Company Profile:
Brainsway Ltd. is dedicated to the development
and marketing of Deep TMS (Transcranial
Magnetic Stimluation) systems - novel,
noninvasive medical devices for the treatment of
a wide range of neurological and
psychopathological disorders. In principle, any
brain-related disorder that is associated with
pathological activity of specific brain sites may be
treated by this method. Potential applications
include addiction, schizophrenia, obesity, eating
disorders, Parkinson's disease, Alzheimer's
disease, autism and post-traumatic stress
disorder. Our initial focus is the treatment of
major depression. The unique technology of
Brainsway is based on patents filed by the U.S.
National Institute of Health (NIH) and by the
company. Brainsway has an exclusive license
from the NIH for the patent and technology.
Headquartered in Jerusalem, Israel, the
company’s ordinary shares and warrants trade on
the Tel Aviv Stock Exchange under the symbol 'BRIN'.
Technology Description:
Transcranial magnetic stimulation (TMS) is a noninvasive technique used to apply brief magnetic pulses to
the brain. The pulses are administered by passing high currents through an electromagnetic coil placed
adjacent to a patient's scalp. The pulses induce an electric field in the underlying brain tissue. When the
induced field is above a certain threshold, and is directed in an appropriate orientation relative the brain's
neuronal pathways, localized axonal depolarizations are produced, thus activating the neurons in the
relevant brain structure. Standard TMS coils are limited to activation of only cortical brain regions, up to a
depth of about 1.5 cm. The unique technology of Brainsway Deep TMS System enables direct non-invasive
activation of deep brain structures. Deep TMS is a breakthrough in the search for a non-invasive approach
for treating common brain disorders. Deep TMS uses a unique, patented coil design to produce directed
electromagnetic fields that can induce excitation or inhibition of neurons deep inside the brain. The
treatment is non-invasive, with no significant side effects, no systemic effect (in contrast to drugs), and no
need of hospitalization or anesthesia.
Company Name: Brainsway Ltd.
Contact Details
Address: 19 Hartom St. By-Net
Building, Jerusalem 91451 ISRAEL
Phone: 972-2-5824030
Fax: 972-2-5812517
Email: [email protected]
Website: www.brainsway.com
Exhibition Representatives
Name: Ronen Segal, CTO
E-mail: [email protected]
Contact Person
Name: Ronen Segal, CTO
E-mail: [email protected]
12 | P a g e
Company Profile:
Compugen (NASDAQ: CGEN) is a leading
oncology and immunology therapeutic discovery
company focused on biologics with a novel
mechanism-of-action to address significant
unmet medical needs.
The Company utilizes a broad and continuously
growing integrated infrastructure of proprietary
scientific understandings and predictive
platforms, algorithms, machine learning systems
and other computational biology capabilities for
the in silico (by computer) prediction and
selection of product candidates, which are then
advanced in its Pipeline Program.
Compugen's broad Pipeline Program consists of
Fc-fusion proteins and monoclonal antibody
(mAb) therapeutics in immunology and
oncology. In the field of novel immune
checkpoints, the Company's pipeline includes
novel members of the B7/CD28 protein family, including CGEN-15001 and CGEN-15021
therapeutic protein candidates showing promising animal model results with potentially unique
mechanisms-of-action, for both multiple sclerosis and rheumatoid arthritis, as well as CGEN-
15001T and CGEN-15022 showing exciting potential as antibody targets for cancer
immunotherapy.
As part of the Pipeline Program, the Company established in-house drug development expertise
for Fc fusions development. More recently, in March 2012, Compugen established operations in
South San-Francisco for the development of oncology and immunology mAb therapeutic
candidates against Compugen drug targets.
The Company's business model includes early stage collaborations and licensing for further
development and commercialization of selected product candidates from its Pipeline Program, as
well as research and discovery collaborations for the discovery of novel targeted medicines
according to the partner's interest.
Company Name: Compugen Ltd.
Contact Details
Address: 72 Pinchas Rosen St., Tel-
Aviv, Israel
Phone: +972-3-7658-585
Fax: +972-2 3-7658-555
Email: [email protected]
Website:www.cgen.com
Exhibition Representatives
Name: Tsipi Keren-Lehrer
E-mail: [email protected]
Contact Person
Name: Tsipi Keren-Lehrer
E-mail: [email protected]
Category: Drug Discovery
13 | P a g e
Company Profile:
While one in three people suffers from a brain
related disorder, due to the brain's complexity,
currently available tools and technologies are
often insufficient to lead to accurate and
objective treatment decisions. ElMindA, a
leading innovator in neuro-technology, is
addressing this significant unmet need with its
BNA™ platform technology. ElMindA's
disruptive platform allows high resolution
visualization and evaluation of the complex
interconnections of the human brain at work.
This unique capability can dramatically enhance
the diagnosis and treatment of brain disorders
and injuries. ElMindA’s patented and patent-
pending technology platform has led to early
partnerships with top pharmaceutical
companies, leading neurological and psychiatric
institutes, NFL and college sports teams, and
numerous grant funding agencies.
Technology Description:
ElMindA has developed a novel functional brain imaging approach that can concurrently reveal
brain networks that are activated while performing and measuring neuropsychological function.
The technology, known as Brain Network Activation, or BNA™, is applicable in a variety of
cognitive domains, pain and motor function among others. This objective, non-invasive approach
has many advantages over other imaging approaches in addition to being cost- effective and time-
sensitive. Using standard multi-channel EEG/ERP technology this system is simple and can easily
be used at any clinical site, at multiple time points and with numerous drug doses. BNA TM system
data are processed and presented both qualitatively and quantitatively, as spatio-temporal images
of network activation patterns (providing detail on location, timing, frequency, connectivity,
synchronization and amplitude of electrophysiological activity and derived measures) and as a
standardized score for group and individual functional activation patterns. Scores on measures of
cognitive performance (e.g., executive function, memory) are also provided. In the drug
development arena, BNA™ provides unique information on mechanism and likely therapeutic
utility providing comprehensive data to understand drug action and to select doses at any phase
of drug development.
Company Name: ElMindA
Contact Details
Address: 16 Haminhara street,
Herzliya,
Israel 46586
Phone: 972-9-9516476
Fax: 972-9-951-6477
Email: [email protected]
Website:www.elminda.com
Exhibition Representatives
Name: Dr. Eli Zangvil
E-mail: [email protected]
Contact Person
Name: Chen Golan
E-mail: [email protected]
Category: CNS
14 | P a g e
Company Name: Foamix Ltd.
Contact Details
Address: 2 Holzman St. Rehovot, Israel
Phone: +972-8-9316233
Fax: +972-8-9474356
Email: [email protected]
Website: www.foamix.co.il
Exhibition Representatives
Name: Dr. Dov Tamarkin
E-mail: [email protected]
Contact Person
Name: Dorit Hayon
E-mail: [email protected]
Category:
Pharmaceutical/Biopharmaceutical
Company Profile:
Foamix is a clinical-stage specialty pharmaceutical
company, focused on the development of proprietary
topical foam and OilGel™ products for dermatology,
gynecology, and ophthalmic disorders. Our
development capabilities range from formulation
development to scale-up, GMP manufacturing,
preclinical and clinical studies.
Partnership: Foamix collaborates with leading pharmaceutical companies to create advanced products with superior convenience, compliance and efficacy, which are backed by an extensive IP.
Intellectual property: To date Foamix has 49 issued patents worldwide of which 15 are in the U.S. and over 60 patents pending in the U.S.
Pipeline: Foamix has a strong in-house foam product pipeline, including conticosteroids, antibiotics, antifungals, antiviral drugs and immunomodulators. The Company’s lead product is a Topical Minocycline Foam.
Lead Product- Minocycline Foam
Foamix’s Minocycline Foam is a First-in-Class topical antibiotic, under development for skin infections, acne and rosacea.
Excellent phase II results in Impetigo patients:
- 80% of the patients improved after 3 days of treatment. - Clinical success in 100% of the patients on Day 7 (end of treatment) and Day 14 (follow-up).
- All MRSA infections were cured following 7 days of treatment.
- No drug related side effects were noted.
Phase II studies in acne and rosacea are underway.
Minocycline Foam is targeted to be the first dermatological blockbuster and captures a market of over 1 billion dollars.
Technology Description:
Technological platforms: Foamix developed eight distinct foam platforms including emulsion foam, waterless foam, ointment foam and oil foam. These versatile platforms enable the incorporation of every drug, including water-soluble, oil-soluble, and particulate compounds in foam. Improved topical treatment: Foams offer an innovative and more convenient means of topical treatment of the skin. This advantage of Foamix’s foam leads to improved compliance and better efficacy.
15 | P a g e
Next-Generation Accelerators for Proton-Beam Cancer Therapy
Company Profile:
HIL Applied Medical is developing a
compact, low-cost accelerator for cancer
proton-beam therapy based on high-
power lasers and nanotech targets. HIL
aims to become the leading provider of
accelerators and related services to PT
system manufacturers; think “Intel
Inside”. HIL is a privately held company,
funded by the Hebrew University in
Jerusalem, Israel’s Office of the Chief
Scientist and private investors.
We are seeking next-round funding as
well as strategic collaborations with
proton therapy / radiotherapy
international players.
Technology Description:
Proton beam therapy can help 300,000
cancer patients/year (US) - yet only 8,000
receive it (that's less than 3%). Protons
are arguably the most advanced form of radiation therapy - yet there are only 10 proton-therapy
centers in the US (compare with 2,700 X-Ray radiation centers). The barrier to adoption is that
proton centers are prohibitively expensive to build and operate, primarily because at their heart
are accelerators that rely on technology from the ‘30s.
We are applying a patented laser-based approach to particle acceleration. This technological
breakthrough enables dramatic reduction the size, complexity and cost of a proton therapy
system. Reduced shielding requirements also contribute to substantial reduction in facility
footprint and building costs (which today account for over 25% of total facility price tag). The
unique properties of laser-accelerated proton beams allow for further savings – 10X or more – in
ancillary magnetic systems used for beam delivery, while providing state-of-the-art clinical
capabilities such as pencil-beam scanning, gating, adaptive therapy, etc.
A complete single-room system based on HIL’s accelerator is estimated to cost $8-12M –
depending on configuration (with/without gantry, etc.), vs. the competitors’ $30-40MM.
Company Name: HIL Applied Medical, Ltd.
Contact Details
Address:
Hi-Tech Park 4/5, #111-112
Edmond J. Safra Campus, Givat Ram
P.O Box 39011, Jerusalem 91390
Phone/fax: (+) 972-2-582-5443
Email: [email protected]
Website: www.hilappliedmedical.com
Exhibition Representatives
Name: Sagi Brink-Danan
E-mail: [email protected]
Contact Person
Name: Shmulik Eisennman
E-mail: [email protected]
Category: Medical Devices
16 | P a g e
Company Profile:
IMMUNE Pharmaceuticals is a global
clinical stage bio-pharmaceutical
company resulting from the merger of a
privately held Israeli company, and
EpiCept Corporation (“EpiCept”)
(NASDAQ OMX Stockholm Exchange and
OTCQX: EPCT). The combined company
is focused on developing antibody
therapeutics and other targeted drugs
for the treatment of inflammatory
diseases and cancer. IMMUNE’s lead
product candidate, BERTILIMUMAB, is a
first in class fully human monoclonal
antibody that targets eotaxin-1, a
chemokine involved in eosinophilic
inflammation, angiogenesis and
neurogenesis. Immune has initiated a
placebo-controlled, double-blind Phase II clinical trial with bertilimumab for the treatment of
ulcerative colitis and plans to initiate in 2013 additional clinical studies in severe asthma, in
bullous phemphigoid, a dermatological orphan condition and in Verneal Kerato-conjunctivitis, an
ocular orphan condition. The companies’ collective oncology portfolios comprise: Immune’s
NanomAbs®, a new generation of antibody drug conjugates, and EpiCept’s vascular disruptive
agents. Immune Pharmaceuticals will continue efforts to secure a development partner for
EpiCept’s Phase III clinical development candidate AmiKet™, for which the FDA has granted Fast
Track designation for the treatment of chemotherapy-induced neuropathic pain.
Status: IMMUNE-EPICEPT pipeline includes four clinical stage assets:
- AMIKET Chemotherapy Induced Peripheral Neuropathy - Phase III
- Bertilimumab Ulcerative Colitis, Severe Asthma, Bullous Pemphigoid, VKC Phase II
- Azixa Brain Tumors Phase II
- Crolibulin Solid Tumors Phase II
Technology Description:
NanomAbs are conjugates of drug loaded nano-particles and monoclonal antibodies, a novel alternative to Antibody Drug Conjugates. They allow targeted delivery of anti-cancer agents to tumor cells. This technology was developed by Professor Benita at Hebrew University of Jerusalem and has been licensed by IMMUNE from YISSUM. IMMUNE is advancing its own candidates toward the clinic. IMMUNE is also making the technology available as part of co-development agreements.
Company Name: IMMUNE Pharmaceuticals
Contact Details
Address: Aba Even 15, Herzliya. Israel
Phone: +972-9 8866612
Email: danit.shema@immune pharma.com
Website: immunepharmaceuticals.com
Exhibition Representatives
Name: Anna Baran
E-mail: [email protected]
Contact Person
Name: Danit Shema
E-mail: [email protected]
Category: Biotechnology/Monoclonal
antibodies
17 | P a g e
Company Profile:
Immune System Key Ltd. was founded in 2005
by two scientists, Prof. Uziel Sandler and Dr.
Yoram Devary. It is a privately owned
biopharmaceutical company. ISK is engaged in
the development of drugs, which are based on
the novel human hormone-peptides that play a
key role in regulating the body’s immune
response. ISK’s flagship compound is NerofeTM.
The synthetic peptide NerofeTM is a derivative of
“Tumor-Cells Apoptosis Factor (TCApF)”, which
was isolated and cloned from thymus and found
to have powerful anti-cancer and anti-
inflammatory properties. ISK intends to advance
NerofeTM in acute myelogenous leukemia (AML)
as first indication and has obtained an orphan
drug status for the use from the FDA (USA). In
2012 the company begins phase I clinical trials of
NerofeTM in solid tumours and final results are
expected by 2013. ISK plans to conduct clinical
trial also in in acute myocardial infarction (heart
attack).
Technology Description:
NerofeTM binds the T1/ST2 receptor. Binding NerofeTM to the T1/ST2 receptor caused a rapid
activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells and
induces apoptosis (programmed cell death) in cancer cells. NerofeTM induced apoptosis in many
different types of cancer cells but not in healthy normal cells. Animal experiments have shown
that NerofeTM slowed down or stopped of the cancer progression in acute myeloid leukemia
proliferating cells, in human breast carcinoma, human lung cancer, human prostate cancer,
human glioblastoma and human neuroblastoma proliferating cells. As an anti-cancer therapy,
NerofeTM has many advantages: it directly induces apoptosis without damaging healthy tissues
and activates the immune system. NerofeTM has also been shown to inhibit angiogenesis, the
formation of new blood vessels in tumours. In lower concentrations, NerofeTM was found to have
an anti-inflammatory and anti- myocardial infarction effects.
Company Name: ISK - Immune
System Key
Contact Details
Address: 9/7 Rosenblatt St.,
Jerusalem, Israel 97460
Phone: +972 50 2597031
Fax: +972 2 6751179
Email: [email protected]
Website: www.immuneSK.com
Exhibition Representatives
Name: Prof. Uziel Sandler
E-mail: [email protected]
Contact Person
Name: Prof. Uziel Sandler
E-mail: [email protected]
Category: Bio Pharma
18 | P a g e
Company Profile:
IonMed Ltd, a privately held biotechnology
company, was founded in 2009 and focuses on
the development of advanced incision closure
technology. IonMed’s welding Device (BioWeld-
1) is bringing an innovative and strategic product
to the incision closure market. The main benefits
of this new technology are the ease of use, cost
reduction and clinical outcomes improvements.
BioWeld-1 will initially target obstetric hospitals
(C-section) followed by the ER (trauma). The
Bioweld-1 closes incisions using cold plasma and
incorporates the use of a special solder
(Chitoplast). The procedure is relatively short,
seals the area completely, leaves minimal
scarring, and can be done without special
training. BioWeld-1’s unique product design is
based upon extensive market research; the
competitive advantages include automatic
mechanism, ease of use, clinical advantages and cost reduction markets. The BoiWeld-1 is well
protected by several submitted patents. Additionally, extensive IP strategy work has been
conducted by the firm Finnegan from Washington, DC. IonMed has developed advanced
prototypes and has held a few clinical trials for the closure of incision post Cesarean-delivery.
There are around 34 million surgical wounds (ambulatory) a year in the US alone where market
size is estimated to be $2.1 billion. The wound closure market’s average annual growth is 3%. The
C-section market alone is estimated to be 4M procedures in the US and Europe.
Technology Description:
The “BioWeld1” welds incisions using a unique cold plasma jet and incorporates a special solder
made of Chitosan. The procedure takes only a few minutes, seals the area, leaves minimal
scarring, and can be done without special training. The new biowelding technology brings some
added values to this traditional market:
Sealing of the incision with less risk of infection and reduction in number of hospital acquired
infections.
Fast and easy to perform incision welding procedure
Reduces healing time by promoting the natural healing mechanism
Reduces tissue scarring
Company Name: IonMed
Contact Details
Address Hacochav Building, 6th
Floor. Hacarmel St., P.O. Box 541.
Yokneam Illit 20692, Israel
Phone: 049591393
Fax: 049591395
Email: [email protected]
Website: www.ion-med.com
Exhibition Representatives
Name: ronen Lam, Amnon Lam
E-mail: [email protected]
Contact Person
Name: ronen Lam
E-mail: [email protected]
19 | P a g e
Company Profile:
The Israel Tech Transfer Organization (ITTN)
serves as the umbrella organization for Israel’s
technology transfer companies.
These companies are affiliated with the
country’s world-renowned universities,
hospitals, HMO and research institutions.
Currently, the 12 partnering organizations
comprise the shareholders. ITTN is a private
non-profit organization.
The Partnering Organizations
ITTN’s partners are affiliated with some of the
world’s leading educational, hospitals and
research institutions.
Yeda Research & Development Company Ltd. (Weizmann Institute of Science)
Yissum Ltd. (Hebrew University of Jerusalem)
Bar–Ilan Research & Development Ltd. BGN Technologies (Ben-Gurion University of the Negev) BioRap Technologies Ltd. (Rappaport Research Institute of the Technion-Israel Institute of
Technology) Carmel-Haifa University Economic Corp. Ltd. (University of Haifa) Gavish Galilee Bioapplications Ltd. (MIGAL Galilee Technology Center) Hadasit Ltd. (Hadassah Medical Organization) Mor Research Applications (Clalit Health Services) Ramot at Tel Aviv University Ltd. T3 – Technion Technology Transfer (Technion Research & Development Foundation Ltd.) Tel Aviv Medical Center
Technology Description:
ITTN showcases novel technologies and biotech startups that were created by its member
organizations. All are in R&D development stages and seek further investment.
Company Name: ITTN
Contact Details Address: Yeda R&D Co. Ltd; Hertzel 240, P.O 95, Rehovot 76100, ISRAEL Phone: +972-8-9470617 Fax: +972-8-9470739 Email: [email protected] Website: www.ittn.org.il Exhibition Representatives Name: Amir Naiberg, Yaacov Michlin E-mail: [email protected] [email protected]
Contact Person Name: Amir Naiberg, Yaacov Michlin E-mail: [email protected] [email protected]
20 | P a g e
Company Profile:
Oramed Pharmaceuticals (ORMP) is developing
proprietary technology for the oral delivery of
drugs presently administered by way of injection.
The technology is based on over 30 years of
research at Hadassah Medical Center in Jerusalem.
Oramed is paving the way to revolutionize the
treatment of diabetes, through its flagship orally
ingestible insulin product and an oral exenatide
capsule.
Technology Description:
Oramed’s novel oral delivery technology offers
peptides protection from gastric breakdown as
they travel through the gastrointestinal tract. The
formulation also enhances drug absorption across
the membrane of the small intestine, whereupon
they travel via the portal vein to the liver and from
there to the systemic circulation. Dosing in this way has the potential to increase patient
compliance and decrease the incidence of side effects often experienced with injections. Phase 2
clinical trials on Oramed’s insulin capsule have validated the clinical relevance of this revolutionary
technology, whose platform can be utilized for a broad spectrum of drugs currently delivered via
injection.
Team: Oramed is endorsed and directed by prominent leaders in the field of research and
development, including: Professor Avram Hershko, recipient of the 2004 Nobel Prize in Chemistry;
Professor John Amatruda, former Senior Vice President of Merck and Co., Inc.; and Dr. Michael
Berelowitz, former Senior Vice President at Pfizer, Inc., and currently the Chairman of the Oramed
Scientific Advisory Board.
Pipeline
Oral Insulin (ORMD-0801) Phase 2 clinical trials
Oral Exenatide (ORMD-0901) Phase 1b/2a clinical trials
Combination Therapy The two formulations performed synergistically (ORMD 0801 + 0901) in preclinical trials; Clinical trials on diabetic patients are expected to follow
Company Name:
Oramed Pharmaceuticals
Contact Details
Address: Kefar Hi-tech 2/5 Givat
Ram, P.O. Box 39098 Jerusalem,
Israel 91390
Phone: +972-2-566-0001,
(US) 1-646-240-4193
Email: [email protected]
Website: www.oramed.com
Exhibition Representatives
Name: Nadav Kidron, CEO
E-mail: [email protected]
Category: Biotech and Drug Delivery
21 | P a g e
Company Profile:
PixCell Medical Technologies is a privately held
company developing Cell-Based Diagnostic
devices for the Point of Care (POC). PixCell's
Viscoelastic Focusing and automated sample
preparation propriety technology present a
breakthrough in live-cell diagnostics, allowing
small-sized, simple and inexpensive testers that
are accurate and robust. PixCell Medical was
founded by Prof. Max Herzberg, a leading figure
in Israel’s biotech industry, and Dr. Avishay
Bransky, an expert on microfluidics and the
inventor of the technology. PixCell’s first
product, HemoScreen – a Complete Blood Count
(CBC) system for the Point of Care – is expected
to be CE approved during 2013.
Technology Description:
PixCell core technology allows for cell-based
diagnostics at the point of care. The core technology is comprised of an Analyzer and a Self-
Contained Disposable Cartridge.
Viscoelastic Focusing – a new physical phenomenon that was recently discovered at the
Technion – Israel Institute of Technology and is exclusively licensed to PixCell Medical.
Viscoelastic Focusing causes cells, which are suspended in the proprietary fluid, to perfectly
align i.e. focus and facilitate their optical detection and analysis.
Disposable Cartridge – PixCell’s patent pending self-contained single-use cartridge enables
whole blood sample collection and automated sample preparation including labeling, staining
and incubation.
Novel Microfluidic Chip – The pure plastic chip is based on a propriety design which facilitates
simultaneous multiple analyses on the same sample.
Image-Based Analysis – advanced machine-learning algorithms are employed in order to
analyze the sample instantly.
Data Management and Reports – Results are displayed on an LCD screen and may be printed or retrieved from a remote clinical information system.
Company Name: PixCell Medical
Technologies Ltd.
Contact Details
Address: 6 Hayezira st. Yokneam Ilit
Phone: +972-4-9593516
Fax: +972-4-9593518
Email: [email protected]
Website: www.pixcell-medical.com
Exhibition Representatives
Name: Dr. Avishay Bransky
E-mail: [email protected]
Contact Person
Name: Hanan Ben-Asher
E-mail: [email protected]
22 | P a g e
Company Profile:
Pluristem is a biotechnology company that is
developing off-the-shelf cell therapies for a variety
of human diseases. Pluristem’s cell products are
derived from human placentas, traditionally left to
be medical waste following childbirth. Pluristem
then expands these placental-derived cells with the
use of a unique, proprietary, three-dimensional
(3D) technology platform that insures the efficient,
controlled, mass production of the Company’s cell
therapy products, termed PLacental eXpanded
(PLX) cells. PLX cells act by secreting therapeutic
chemokines, cytokines and growth factors in
response to signals produced by inflammatory and
ischemic conditions within the body. PLX cells are
readily available and require no tissue matching
prior to administration.
Technology Description: Pluristem’s PLX cells are mesenchymal-like adherent stromal cells (ASCs)
derived from full term human placentas. These cells are expanded in the company's proprietary
bioreactor system that creates a three-dimensional (3D) microenvironment. This 3D technology
allows for the controlled, large-scale growth of cells implementing an optimized, standardized,
scaled-up and “hands-off” operation. This allows PLX cells to be mass-produced with batch-to-
batch consistency for a fraction of the cost of traditionally expanding cells using tissue flasks.
Furthermore, Pluristem’s 3D expansion technology allows for the production of specific PLX cell
products for each of the Company's targeted indications. PLX cells grown with Pluristem's 3D
technology are "bar coded" during their manufacturing process. Pluristem has a strong patent
portfolio, GMP certified manufacturing, research and development facilities of over 40,000 square
feet and a strong balance sheet. The company also maintains strategic relationships with a major
pharmaceutical company and research institutions around the globe.
Company Name: Pluristem
Therapeutics
Contact Details
Address: MATAM Advanced
Technology Park, Building #20, Haifa
31905, Israel
Phone: +972-74-710-7100
Fax: +972-74-710-7172
Email: [email protected]
Website: www.pluristem.com
Exhibition Representatives
Name: Daya Lettvin
E-mail: [email protected]
Contact Person
Name: William Prather
E-mail:
23 | P a g e
Company Profile: PolyPid Ltd is a privately held Israeli biotechnology
company that is developing a novel and patented
nanotechnology delivery platform that controls the
release profile, rate and duration of drugs for as
long as many months. The entrapped drug reservoir
is fully protected from hostile and hydrated in vivo
degradation. PolyPid’s first focus is BonyPid™, a
local delivery platform designed to treat bone
morbidities (orthopedic and dental). BonyPid™ fills
an unmet need due to current poor performance in
both systemic treatment and local solutions. The
first-in-man study for the treatment of
contaminated/infected severe open long-bone
fractures of BonyPid™ loaded with antibiotics is in
its follow-up stage, and will be completed by May
2013. In addition, a European phase II clinical trial
has been initiated. The antibacterial BonyPid™ used in these studies is a synthetic bone void filler device
coated by a thin layer (≤20 µm) of PolyPid formulation. Upon implantation, the coating releases a broad
range antibiotic (doxycycline) at a constant rate for a predetermined period of 30 days. Preliminary
results (12 week follow up) have demonstrated safety and a positive signal of BonyPid™ effect in severe
fractures resulted by early bone formation and anti-infective effects (no infection was reported at the
target fractures). Due to the risk of infection, bone grafts which do not include antibiotics are
contraindicated in contaminated or infected bones, and therefore commonly used only after multiple
surgical procedures and prolonged hospitalizations. Because BonyPid™ can be immediately implanted
into the contaminated/ infected bones during the patient’s initial surgery; it has the potential to reduce
the number of costly procedures and hospitalizations.
Technology Description:
Many drugs can be used- including small molecules, peptides, proteins and nucleic acids
Protected drug reservoir - protection from in vivo hydration and enzymatic degradation
Prolonged duration - Days >>Weeks >> Months: Pre-programmed as per need
Constant and controlled release rate - Pre-programmed as per need
Combination - More than one drug can be used All ingredients are already used in the pharmaceutical industry. No chemical bonds are formed
between the drug and the formulation compounds
Administration – Coating of medical devices as well as pure structures Polypid is taking part in both Israeli and European consortiums that explore the benefits the platform
provides in delivery of therapeutic siRNA molecules, and delivery of anti-biofilm peptides (EU FP7).
Polypid is receptive to a range of business models including licensing, co-development, joint ventures,
business and marketing alliances, and other forms of cooperation.
Company Name: PolyPid
Contact Details
Address: 20 Hamgshimim St., Petach-
Tikva, Israel
Phone: +972-747195700
Fax: +972-747195718
Email: [email protected]
Website:www.polypid.com
Exhibition Representatives
Name: Amir Weisberg, Noam Emanuel
E-mail: [email protected]
Contact Person
Name: Dr. Noam Emanuel
E-mail: [email protected]
24 | P a g e
Company Profile:
Protalix is a publicly traded (NYSE: PLX, TASE),
biopharmaceutical company that is
revolutionizing the development and
manufacturing of recombinant therapeutic
proteins through its ProCellEx® plant cell-based
protein expression system.
Protalix’s first approved product is ELELYSO™
(taliglucerase alfa for injection) for the
treatment of Gauchers disease, which received
approval from the U.S Food and Drug
Administration on May 1, 2012 and from the
Israeli Ministry of Health on September 27,
2012. ELELYSO is the first FDA-approved plant
cell-based recombinant therapeutic protein.
Platform Technology Description:
ProCellEx® is a proprietary production system
that is based on plant cell culture technology
for the development, expression and manufacture of recombinant proteins. This system consists
of a comprehensive set of capabilities and proprietary technologies, including advanced genetic
engineering and plant cell culture technology, which enables us to produce complex, biologically
equivalent proteins for a variety of human diseases.
Pipeline:
Company Name: Protalix
Biotherapeutics
Contact Details
Address: 2 Snunit St. Science Park,
Carmiel, Israel
Phone: 972-4-9028100
Fax: 972-4- 9889489
Email: [email protected]
Website: www.protalix.com
Exhibition Representatives
Name: Elisha Nathan
E-mail: [email protected]
Contact Person
Name: Elisha Nathan
E-mail: [email protected]
25 | P a g e
Company Profile:
Proteologics Ltd. (TASE “PRTL”) is a drug
development company that specializes in
transforming its world-class knowledge of the
ubiquitin-proteasome system (UPS) into novel
small molecule therapeutics. Proteologics unites
a team of passionate scientists, business leaders
and Nobel Prize laureates, bringing together
their collective experiences in UPS-based drug
discovery. Dr. Avram Hershko and Dr. Aaron
Ciechanover – 2004 Nobel Prize laureates for the
discovery of the ubiquitin system – lead the
company’s scientific advisory board.
Proteologics’s scientific excellence is supported
by a unique drug discovery platform, which
implements state of the art technologies along
with proprietary UPS-related tools for the
generation of a sustainable pipeline of small
molecules. Proteologics is a public company
trading on the Tel Aviv Stock Exchange. Investors
include GlaxoSmithKline Plc. and leading Israeli
venture capital and biotech companies.
Business Model
Proteologics believes in partnering its innovation expertise with the supporting infrastructure of
larger pharmaceutical companies, to create a strong additive value for both sides.
Collaborations
In February 2010 Proteologics signed a collaboration agreement with GlaxoSmithKline
LLC. (GSK) to collaborate on six cancer drug discovery programs over the next three
years.
In September 2008, Teva Pharmaceutical Industries Ltd. licensed three cancer early
drug development programs.
Collaborations with Academy: Proteologics established several collaborations with
leading research lab all over the world.
Company Name: Proteologics Ltd.
Contact Details
Address: 2 Holzman St
Phone: +972-8-9475-666
Fax: +972-8-9475-999
Email: [email protected]
Website: www.proteologics.com
Exhibition Representatives
Name: Avishai Levy
E-mail: [email protected]
Contact Person
Name: Avishai Levy
E-mail: [email protected]
Category: Drug Discovery
26 | P a g e
Company Profile:
RDD Pharma Ltd., an Israeli biotechnology
enterprise, will become the leader in the discovery,
development, and commercialization of innovative
therapeutics for Ano-rectal diseases. The company
was founded in Ofakim incubator (OHV) and
current major shareholders include Orbimed. The
Ano-Rectal disease market is multibillion in size
and yet hardly touched by the drug industry. RDD
target indications are Anal Fissure and Fecal
Incontinence in patients with spinal cord injury.
Technology Description:
In order to safely and effectively apply a drug to
the ano-rectal region, two challenges needs to be
addressed: application to the intra-anal region
which will reduce the systemic absorption of the
drug, AND special formulation of the drug to meet
the physiology of the region. RDD Pharma Ltd has
developed the Cappository which is a drug-
delivery-method that meets these challenges, and
built the know-how for the suitable drug formulations for this area of the body.
Anal fissure: There are over 2.5 M patients in the US and EU that suffer from this disease each
year. Current medical treatment options cause debilitating headaches in 65% of users. RDD
Pharma Ltd conducted proof-of-concept trial in 20 patients and found that the Cappository
technology provided quick, safe and efficacious relief. The company now prepares a large scale
multi-national study that will serve as a phase 3 study for Europe and a phase 2 study for the US.
Fecal Incontinence: No medical treatment is available for this condition that affects 1 out 8 adults.
RDD Pharma focus is on patients with fecal incontinence due to spinal cord injury. Currently there
are about 200,000 spinal cord injury patients that suffer from fecal incontinence, and this
condition is a major contributor to morbidity, mortality and hospital stay in this population. The
company completed a proof of concept study in healthy subjects and found that this product
provided a significant and long lasting contraction of the anal sphincter. The company is now
completing the bridging studies for this product and intends to enter clinical phase of
development within a year.
Company Name: RDD Pharma Ltd
Contact Details
Address: 31 Habarzel St, 69710,
Israel
Phone: +972-722-419-061
Fax: +972-722-419-062
Email: [email protected]
Website: www.rddpharma.com
Exhibition Representatives
Name: Nir Barak MD
E-mail: [email protected]
Contact Person
Name: Nir Barak MD
E-mail: [email protected]
Category: Pharma
27 | P a g e
]
Company Profile:
Shulov Innovative Science Ltd. (S.I.S) is a
privately owned bio-pharmaceutical company
focused on the development of novel human
therapeutics. S.I.S has identified, and isolated
several novel non-toxic natural peptides. These
peptides are bio-active as anti-viral, anti-
psoriasis and painkiller molecules upon topical
application (granted US patent). S.I.S products
are short synthetic peptides formulated as a
cream. The product coded Zep-3, was assessed
for its safety and efficacy in several pre-clinical
in-vitro and in-vivo studies. Zep-3 cream
demonstrated anti-viral activity in various in
vivo, ex-vivo and in vitro studies. Zep-3 inhibited
the replication and spreading of Herpes Simplex
Virus Type 1 (HSV1) in a dose dependent
manner. S.I.S has conducted a large variety of
pre-clinical in-vitro and in-vivo animal studies in
accordance with the requirements of the health
regulatory authorities and in order to support
the development processes of Zep-3 and to
establish its safety, tolerability and efficacy. S.I.S
is geared to complete in Q1 2013 the Phase I clinical study and start at the end of Q3 2013 a Phase
II clinical study for the HSV1 Cold Sores indication as well as a Phase I / IIa clinical study to treat
Genital Herpes induced symptoms. Currently, the company is looking for a strategic partner for
Zep-3 in order to assist the company in performing Phase II and beyond.
Technology Description:
S.I.S has a long term contract with the Israeli Ministry of Health to supply snakes venoms from its
serpentarium for the preparation of antidotes under GMP requirements. In addition, the company
has a unique experience in setting-up in vivo assays to facilitate identification and isolation of non-
toxic bio-active molecules that have therapeutic potential (anti-viral, anti-psoriasis, analgesics and
others). S.I.S holds granted US patent that is in various stages of approval worldwide for all said
peptides, their various analogs and their potential therapeutic use. Recently, a new PCT patent
was submitted (#PCT/IL2012/050105) claiming the therapeutic use of the peptides in skin edemas
and disorders, such as HSV1 and HSV2 induced symptoms as well as Chicken Pox and Psoriasis.
Company Name: S.I.S Shulov
Innovative Science Ltd.
Contact Details
Address: 10 Oppenheimer,
REHOVOT ISRAEL
Phone: 972-8-9314114
Fax: 972-8-9471062
Email: [email protected]
Website: www.sis-shulov.com
Exhibition Representatives Name:
Dr. Avigdor Levanon
Executive VP, Business Dev.
E-mail: [email protected]
Dr. Naftali Primor, R&D Director
E-mail: [email protected]
Contact Person
Name: Dr. Avigdor Levanon
E-mail: [email protected]
Category: Bio-Pharma
28 | P a g e
Notes ________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
____
29 | P a g e
Notes ________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
____
30 | P a g e
MATIMOP, the executive agency of the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel
(OCS), is the official national agency for industrial R&D cooperation, tasked with generating and implementing
international cooperative industrial R&D programs between Israeli and foreign enterprises.
www.matimop.org.il
